FDA's Drug Delivery Device Draft Guidance: What Combination Product Sponsors Must Prepare

A prefilled syringe, an autoinjector or an inhaler is not just a container. It is the part of the product that decides whether the right dose reaches the patient, every time. On 30 October 2026, the United States Food and Drug Administration published a revised draft guidance that sets out what sponsors must show about how these devices perform. For Canadian companies that develop combination products, or that export them to the United States, the message is clear: the bar for proving drug delivery performance is being raised and made more consistent.

The guidance is called Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products. It is a revised draft, it is open for comment, and it signals how the FDA wants to see drug delivery performance established and assessed across the product lifecycle. This article explains what the guidance covers, what a combination product sponsor should do now, and what Canadian exporters should consider commenting on before the window closes.

Executive summary

The FDA has issued a revised draft guidance on essential drug delivery performance for devices that deliver drugs and biological products. It replaces the 2024 draft on essential drug delivery outputs and focuses on the information needed to show that a device consistently delivers the drug as intended. The guidance applies across investigational, marketing and post-market change applications, and it aligns with the revised Quality Management System Regulation. Comments are open for 90 days. Canadian sponsors and exporters should map their delivery performance evidence to the new expectations now.

Key takeaways:

• The guidance covers combination products that include a device part intended to deliver a human drug, including biological products.
• It replaces the July 2024 draft, Essential Drug Delivery Outputs, and reframes the expectations around essential drug delivery performance.
• The information applies to investigational, marketing and post-market change applications, so it touches the whole lifecycle, not just the original filing.
• The guidance aligns with the revised Quality Management System Regulation (21 CFR part 820), which harmonizes FDA requirements with ISO 13485 and takes effect on 2 February 2026.
• Comments are due about 90 days after the 30 October 2026 publication, which falls at the end of January 2027. Confirm the exact date on docket FDA-2024-D-2560.
• Guidance documents are non-binding, but they describe the FDA's current thinking and shape what reviewers expect to see.

What the guidance is, and what changed

In short: the FDA replaced its 2024 draft on essential drug delivery outputs with a revised draft that it now frames around essential drug delivery performance. The new draft clarifies how to develop, organize and present the information that shows a device delivers the drug consistently and as intended, and it aligns that expectation with the revised quality system rule.

According to the Federal Register notice of availability, the guidance revises and replaces the draft guidance entitled Essential Drug Delivery Outputs Intended to Deliver Drugs and Biological Products, announced on 1 July 2024. It is issued through the FDA's Office of Combination Products. The notice states that the guidance addresses information that is essential for establishing and assessing drug delivery performance for drug delivery devices, and that this information is intended to demonstrate that the device drug-delivery function consistently performs as intended.

What is a combination product, and why does this matter?

Short answer: a combination product pairs a drug or biologic with a delivery device, and the device part is now under sharper scrutiny for how well it delivers the dose. Many of the most common products on the market are combination products, so the guidance reaches a wide set of sponsors.

Drug delivery combination products include prefilled syringes, autoinjectors, pen injectors, on-body and wearable injectors, metered dose and dry powder inhalers, nasal sprays and transdermal systems. The device part is what controls the delivered dose, the delivery rate and the usability of the product. The current good manufacturing practice requirements for combination products sit in 21 CFR part 4, which pulls together the drug and device quality systems. This new draft guidance focuses specifically on the performance evidence for the delivery function, not on the chemistry of the drug itself.

For a sponsor, the practical effect is that the device performance file can no longer be an afterthought bolted onto a strong drug dossier. The delivery device needs its own clear, well organized evidence that it does what the label promises, dose after dose.

What essential drug delivery performance means

Short answer: it is the information that shows the device drug-delivery function consistently performs as intended. The guidance is about how to establish that performance, how to assess it, and how to present the evidence in a way reviewers can follow.

The 2024 draft used the phrase essential drug delivery outputs. The revised draft reframes the same idea around performance: the characteristics and information that are essential to establish and assess whether the device reliably delivers the drug. In plain terms, a sponsor should be able to answer three questions with evidence:

• What does the device have to do? Define the delivery performance the product must achieve for the drug to work as labelled, such as dose accuracy and delivery rate.
• How do you know it does it? Provide the testing and data that establish and confirm that performance, including the specifications and controls that hold it in place.
• How do you keep it doing it? Show how the performance is controlled across manufacturing and maintained through the product lifecycle, including after changes.

Where this information goes in your submissions

Short answer: everywhere the device performance is relevant, from early investigational filings to marketing applications and post-market changes. The guidance is written to improve the consistency of this information across all of those stages.

The Federal Register notice ties the information to existing application types, including investigational filings and marketing and post-market change applications. That means the delivery performance story should be built once, early, and then carried consistently through the product lifecycle. Our guidance on FDA electronic submissions for Canadian device makers and on postapproval manufacturing changes for biologics both touch the same discipline: get the evidence structure right at the start so later changes do not force a rebuild.

How it aligns with the revised quality system rule

Short answer: the guidance is written to fit the revised Quality Management System Regulation. The delivery performance you prove in a submission is the same performance your quality system must control in production.

The notice says the guidance aligns with the revised Quality Management System Regulation, 21 CFR part 820. That revised rule, often called the QMSR, harmonizes the FDA device quality system requirements with ISO 13485 and takes effect on 2 February 2026. For combination products, the device quality system and the drug good manufacturing practices already meet under 21 CFR part 4. The practical message is that delivery performance is not only a submission topic. It is a lifecycle control that your design, risk management and production records must support. A strong ISO 14971 risk management file that links delivery hazards to controls is central to that story.

What Canadian sponsors and exporters should do now

Short answer: treat the draft as a planning document, map your current delivery performance evidence against it, and consider submitting a comment before the window closes. Canadian firms that export combination products to the United States are directly affected.

Health Canada and the FDA both regulate drug-device combination products, and a product that delivers a drug is judged in part on how well the device performs. If you export to the United States, your American submissions will be reviewed against this evolving expectation. The FDA actively invites comment, and a well reasoned comment from a Canadian sponsor can shape the final guidance. We have seen the value of commenting on FDA device draft guidances before, such as the robotic surgical device draft. The same logic applies here.

Steps to take in the next quarter:

• Read the revised draft in full and compare it against the 2024 draft you may have already mapped.
• Inventory your delivery performance requirements, tests and specifications for each combination product, and find the gaps.
• Check that your risk management file links delivery hazards to the controls that prevent them.
• Confirm your quality system is ready for the QMSR transition on 2 February 2026, including design and change controls for the device part.
• Decide whether to submit a comment on docket FDA-2024-D-2560 before the end of January 2027.

Combination product readiness checklist

Use this checklist to test whether your delivery performance evidence will meet the FDA's revised expectations. It is the basis of the downloadable worksheet below.

• Define, in writing, the delivery performance each product must achieve, such as dose accuracy, delivery rate and delivered volume.
• Hold the test data that establish and confirm that performance, with clear links from requirement to test to result.
• Set specifications and in-process controls that keep delivery performance within limits during manufacturing.
• Maintain a risk management file that connects delivery hazards to design and process controls.
• Document human factors and use-related evidence for the delivery device, where the product relies on the user to dose correctly.
• Organize the performance information so a reviewer can follow it across investigational, marketing and post-market applications.
• Align device design and change controls with the QMSR and 21 CFR part 4 before the 2 February 2026 transition.
• Plan how a device, component or process change will be assessed against delivery performance before it is made.
• Track the docket and diarise the comment deadline for docket FDA-2024-D-2560.

Common mistakes to avoid

• Treating the device as packaging. The delivery device controls the dose. Its performance evidence deserves the same rigour as the drug dossier.
• Reusing the 2024 mapping without checking. The revised draft reframes outputs as performance and adds clarifications. A fresh gap analysis is worth the time.
• Building the evidence only for the first filing. The guidance spans the lifecycle. Evidence structured only for the initial application forces costly rework at the first change.
• Leaving the QMSR transition to the quality team alone. Design and change controls for the device part sit at the heart of delivery performance. Regulatory and development must be involved.
• Skipping the comment window. A draft is your best chance to influence the final expectation. Silence is a missed opportunity, especially for exporters.

How MFLRC can help

MFLRC helps combination product sponsors and Canadian exporters build delivery performance evidence that holds up with the FDA and Health Canada. We carry out gap assessments against the revised draft guidance, structure the delivery performance narrative across investigational, marketing and post-market applications, and align device design, risk management and change controls with 21 CFR part 4 and the QMSR. We support regulatory strategy for combination products on both sides of the border, prepare and review comment submissions, and provide the SOPs, validation and audit readiness that make the evidence defensible. For companies managing United States device obligations, we also advise on device establishment registration and listing and higher class device licence expectations.

Whether you are filing your first combination product or maintaining a portfolio of injectors and inhalers, a focused review now will save you a scramble when the guidance is finalized.

Want to pressure test your delivery performance evidence? Talk to MFLRC or book a consultation and we will map your combination products to the FDA's revised expectations.

Frequently asked questions

What does the FDA's revised drug delivery guidance cover?

It covers the information needed to establish and assess that a device consistently delivers a drug or biologic as intended. It applies to combination products that include a device part for delivering a human drug, such as prefilled syringes, autoinjectors, pen injectors and inhalers, and it spans investigational, marketing and post-market change applications.

How is this different from the 2024 draft?

The revised draft replaces the July 2024 draft on essential drug delivery outputs and reframes the expectation around essential drug delivery performance. It updates the content on testing and controlling delivery performance and aligns with the revised Quality Management System Regulation. Sponsors who mapped the 2024 draft should run a fresh comparison.

When is the comment deadline?

Comments are due about 90 days after the 30 October 2026 Federal Register publication, which puts the deadline at the end of January 2027. Confirm the exact closing date on docket FDA-2024-D-2560 at Regulations.gov before you rely on it.

Does this apply to Canadian companies?

Yes, if you develop combination products or export them to the United States. Your American submissions will be reviewed against this evolving expectation, and the comment window is open to international sponsors. Health Canada also regulates drug-device combination products, so the underlying discipline applies at home too.

Is the guidance legally binding?

No. Guidance documents describe the FDA's current thinking and are non-binding on the agency or the public. In practice, reviewers expect submissions to reflect the logic of current guidance, so it is wise to plan as though it applies.

How does this connect to the QMSR?

The guidance aligns with the revised Quality Management System Regulation (21 CFR part 820), which harmonizes FDA device requirements with ISO 13485 and takes effect on 2 February 2026. For combination products, the device quality system and drug good manufacturing practices already meet under 21 CFR part 4, so delivery performance is both a submission topic and a production control.

The bottom line

The FDA is telling combination product sponsors that the delivery device is not a wrapper around the drug. It is a performance system that must be defined, proven and controlled across the product lifecycle. The revised draft guidance on essential drug delivery performance makes that expectation clearer and more consistent, and it ties the evidence to the quality system rule that takes effect in February 2026.

Canadian sponsors and exporters have a short window to align their evidence and, if they choose, to shape the final guidance through a comment. The companies that treat delivery performance as a first class part of the file, not an appendix, will move through review faster and face fewer surprises when the guidance is finalized.

Sources and references

• Federal Register, Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products; Revised Draft Guidance (30 October 2026)
• FDA, Combination Products: Guidance and Regulatory Information
• FDA, Search for FDA Guidance Documents
• 21 CFR Part 4, Regulation of Combination Products (eCFR)
• FDA, What's New Related to Drugs